Napamezole, an alpha-2 adrenergic receptor antagonist and monoamine uptake inhibitor in vitro.
Napamezole (2-[3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydro-1H- imidazole-monohydrochloride) is a selective alpha-2 adrenergic receptor antagonist and a monoamine re-uptake inhibitor in vitro. The alpha adrenergic antagonist activity of napamezole was determined in vitro in rat brain receptor binding assay using [3H]clonidine and [3H]prazosin for alpha-2 and alpha-1 receptors, respectively. The Ki values for napamezole were 28 nM (alpha-2) and 93 nM (alpha-1). The relative potencies for inhibiting [3H]clonidine binding were: phentolamine greater than idazoxan greater than napamezole greater than mianserin greater than yohimbine greater than piperoxan greater than rauwolscine greater than tolazoline much greater than prazosin; and for inhibition [3H]prazosin binding they were: prazosin greater than phentolamine greater than mianserin greater than napamezole greater than yohimbine greater than idazoxan greater than tolazoline. Alpha adrenoceptor antagonism was also assessed in the isolated rat vas deferens. Napamezole reversed clonidine-induced decreased in twitch height in the electrically stimulated rat vas deferens (alpha-2 antagonism with a Kb of 17 nM). The rank order of potency as an alpha-2 antagonist relative to other compounds was phentolamine greater than idazoxan greater than yohimbine greater than piperoxan = napamezole greater than mianserin much greater than prazosin. Napamezole also antagonized methoxamine-induced contractions (alpha-1) of the rat vas deferens with a Kb of 135 nM. The rank order of potency of these compounds as alpha-1 antagonists was prazosin greater than phentolamine greater than mianserin greater than yohimbine greater than napamezole greater than idazoxan.(ABSTRACT TRUNCATED AT 250 WORDS)
Perrone
M H
MH
Department of Pharmacology, Sterling Research Group, Rensselaer, New York.
Hamel
L T
LT
Ferrari
R A
RA
Haubrich
D R
DR
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002478:Cells, Cultured; D003000:Clonidine / Q000378:metabolism; D004146:Dioxanes / Q000494:pharmacology; D019329:Idazoxan; D007093:Imidazoles / Q000494:pharmacology*; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology*; D011224:Prazosin / Q000378:metabolism; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D014649:Vas Deferens / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000596:Amino Acids; D004146:Dioxanes; D007093:Imidazoles; D014179:Neurotransmitter Uptake Inhibitors; D011942:Receptors, Adrenergic, alpha; C065345:napamezole; D003000:Clonidine; D007099:Imipramine; D011224:Prazosin; D019329:Idazoxan